/
Oncology
Hepatocellular Carcinoma
250
Pipeline Programs↗
470
Active Trials↗
140
Companies Involved↗
Hepatocellular Carcinoma is a highly competitive landscape with 250 programs across 140 companies. The most active players are Shanghai Henlius Biotech, AstraZeneca, AbbVie. 52 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical74
Phase 133
Phase 291
Phase 352
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
177 of 220 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 220 classified programs, each share of the total. Modality classified for 97% of 250 pipeline programs.
Analysis
Trial Status
1,258
clinical trials
Completed364 · 29%
Unknown status266 · 21%
Recruiting256 · 20%
Not yet recruiting134 · 11%
Terminated110 · 9%
Active, not recruiting79 · 6%
Other49 · 4%
Clinical Trials
Trial Activity
1258 trials
Page 1 of 84
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)